Martin Walton appointed as Chief Financial Officer

by QuantuMDx Team February 24, 2022

NEWCASTLE UPON TYNE, UK, 24 FEBRUARY 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce the appointment of Martin Walton as Chief Financial Officer.

Martin has over 35 years’ experience working within large global companies with the last 15 years specifically in the life sciences sector. He is currently Chairman and CEO of Bradshaw Consulting Ltd, a Strategic Advisory group assisting companies and shareholders in creating, generating and realising value from investments in life sciences and tech sectors. He also set up and manages Excalibur Medicines Ltd a clinical stage (phase II) virtual biotech, sits on the Board of Minneapolis-based Interrad Medical LLC and is a Partnership Board Member of the Liverpool Life Sciences Accelerator.

Martin Walton, Chief Financial Officer, QuantuMDx, said: “I am very excited to join QuantuMDx. It is a great pleasure to join a company that is doing amazing work bringing a diagnostic platform that will empower the world to control disease and reduce suffering. There is a significant need, in a range of healthcare settings, for a rapid, affordable and accurate point-of-care device with high multiplexing capabilities; Q-POC™ provides this solution. I am looking forward to working with the management team as QuantuMDx continues to evolve”.

Notes to editor:

About QuantuMDx:

QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need, for anyone, anywhere.

QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics.

Q-POC™ is a rapid, simple to use, portable, sample to answer multiplex PCR device. It has been designed for use in a range of real-world settings, such as hospitals, clinics, pharmacies, dentistry, workplaces and in the field, providing accurate PCR results at the Point of Need.

Q-POC™ and its first test, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. It tests multiple targets of the disease for a future proof COVID-19 testing solution at the Point of Need. For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.com.

QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years.

For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.com.